Plain-English translation of NCT06363006 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two medications: cardonilimab (an immunotherapy drug) plus a tyrosine kinase inhibitor or TKI (a targeted cancer drug). You would receive both medications together as a second-line treatment if your advanced liver cancer stopped responding to or didn't tolerate your first cancer treatment. The study will enroll 40 people and track how well this combination works and how safe it is.
Advanced liver cancer is difficult to treat, especially once it stops responding to initial therapy. Doctors hope that combining this immunotherapy medication with a targeted drug might work better by attacking cancer cells in two different ways at once—directly blocking tumor growth while also waking up the immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication cardonilimab as an intravenous infusion every 2 weeks, combined with a tyrosine kinase inhibitor tablet (taken by mouth, as part of standard care). Each infusion takes about 60 minutes, though it can be extended if needed. You would continue treatment for up to 24 months as long as the cancer is responding and you are tolerating the medications well. You will have regular clinic visits for infusions, blood tests, imaging scans, and check-ins with your medical team to monitor how the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China